Han Zeng

Xinqiao, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.

Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.

Journal: Journal for immunotherapy of cancer

Published: May 05, 2026

An Integrated Cell-Death Program Defines Aggressive Prostate Cancer by Coupling Ezrin to the Hippo-YAP/TAZ Axis.

An Integrated Cell-Death Program Defines Aggressive Prostate Cancer by Coupling Ezrin to the Hippo-YAP/TAZ Axis.

Journal: Annals of surgical oncology

Published: February 13, 2026

Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma.

Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma.

Journal: Cancer

Published: February 10, 2026

Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression.

Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression.

Journal: British journal of cancer

Published: October 16, 2025

Natural killer cell infiltration elicits gender-dependent dichotomous clinical outcomes in urothelial carcinoma.

Natural killer cell infiltration elicits gender-dependent dichotomous clinical outcomes in urothelial carcinoma.

Journal: Cancer

Published: October 07, 2025

TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.

TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.

Journal: British journal of cancer

Published: July 24, 2025

ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma.

ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 06, 2025

Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression.

Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression.

Journal: Journal for immunotherapy of cancer

Published: December 13, 2024

HIF-2α-induced upregulation of CD36 promotes the development of ccRCC.

HIF-2α-induced upregulation of CD36 promotes the development of ccRCC.

Journal: Experimental cell research

Published: March 30, 2022

CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis.

CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis.

Journal: Nature communications

Published: December 06, 2021

CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.

CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.

Journal: Molecular metabolism

Published: November 17, 2021

Deletion of CD36 gene ameliorates glucose metabolism abnormality induced by high-fat diet and promotes liver lipid accumulation

Deletion of CD36 gene ameliorates glucose metabolism abnormality induced by high-fat diet and promotes liver lipid accumulation

Journal: Sheng li xue bao : [Acta physiologica Sinica]

Published: October 28, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026